ALK and non-small cell lung carcinoma: It has shown promising efficacy over chemotherapy for patients with disease progression from crizotinib treatment and also patients who have not been previously treated.13, 14 Given the high potency of ceritinib, both against wild‐type ALK as well as a number of gatekeeper mutations,15 ALK‐positive NSCLC patients treated with ceritinib may have a better control of systemic progression than those treated with crizotinib, albeit evidence of the direct comparison between the two drugs is scarce.